Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobimetinib - Genentech/Exelixis

Drug Profile

Cobimetinib - Genentech/Exelixis

Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518

Latest Information Update: 15 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis; Genentech; InxMed; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
  • Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Histiocytosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Registered Histiocytosis
  • Phase III Colorectal cancer
  • Phase II Brain metastases; Breast cancer; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Triple negative breast cancer; Urogenital cancer; Vascular disorders
  • Phase I/II Multiple myeloma; Pancreatic cancer; Solid tumours
  • Phase I Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uveal melanoma
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 05 Apr 2024 Interim adverse events and efficacy data from the phase-Ib/II MORPHEUS-PDAC trial in Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 09 Dec 2023 Adverse events and efficacy data from a phase II trial in Histiocytosis were presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 12 Jul 2023 Roche completes the phase I trial in Ovarian cancer, Peritoneal cancer and Fallopian tube cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in the US, Italy and Spain (PO) (NCT03695380)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top